Shots:
- Novo Nordisk has reported the P-IIIa (PIONEER TEENS) trial assessing oral semaglutide (3, 7 or 14mg, QD) vs PBO, on top of background treatment with metformin, basal insulin, or both, in 132 pts (10-17yrs.) with type 2 diabetes
- Trial showed superior HbA1c reduction vs PBO, lowering blood sugar by 0.83% at 26wks., with a well-tolerated safety profile consistent with prior Novo Nordisk semaglutide trials
- Oral semaglutide is marketed as Rybelsus in the US & EU, and will soon launch in the US as an Ozempic pill, with Novo planning regulatory filings for label expansion for both brands in the US & EU in the H2’26
Ref: Globenewswire | Image: Novo Nordisk | Press Release
Related News: Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
